Ophthalmologists must consider many factors when trying to optimize visual outcomes after cataract surgery in patients with glaucoma. One of the most important is the choice of IOL, both in terms of the material and design and especially regarding the postoperative refractive state planned for the patient. Cataract surgery can definitely improve the quality of vision of patients with even severe glaucoma, but preexisting visual field defects and lost contrast sensitivity will persist even after a successful cataract procedure. These functional defects can adversely influence the desired refractive outcome, particularly for patients who want to be spectacle free after surgery. For these reasons, surgeons must expertly manage glaucoma patients’ expectations and be aware of the potential benefits and limitations of the different IOL options in this population. In particular, the need for caution in pursuing a spectacle-free postoperative outcome rises as the severity of the glaucoma increases.

Ocular Hypertensives and Patients with Early Glaucoma

Patients with ocular hypertension (OHT) and those with very early, stable glaucoma can benefit from any of the available IOL and refractive options. I discuss all of the possibilities with these patients in the same way I would with a cataract patient who does not have OHT or glaucoma. For those interested in monovision or a multifocal IOL, I add to my informed consent a short discussion of the possibility that future disease progression could render these refractive choices somewhat less helpful, but I do not discourage these patients from selecting any IOL or refractive alternative. Rather, I use the same selection criteria and expectations management as I would for any cataract patient.

Patients with Moderate to Severe Glaucoma

Surgeons must take permanent visual deficits into account when choosing an IOL and desired postoperative refractive outcome. Decreased visual function due to glaucoma could reduce the intended effect of some lenses. A few specific options merit special consideration in this population.

Aspheric IOLs

Some newer IOL technologies may be quite beneficial to this population. Moderate to severe glaucoma can decrease patients’ contrast sensitivity. Because aspheric IOLs reportedly produce better contrast sensitivity than conventional lenses, I favor aspheric IOLs for patients with glaucoma, and I have used these lenses successfully in these individuals. I also find aspheric lenses to be highly biocompatible and to have excellent centration.

Toric IOLs

In my experience, modern aspheric toric IOLs can be used very successfully in glaucoma patients, even those with severe disease. I typically would not select a toric IOL with its additional cost if I thought that glaucoma had reduced a patient’s central visual potential, but for many of my glaucoma patients, these lenses provide excellent postoperative results. Aspheric toric IOLs can be particularly effective at reducing astigmatism induced by previous filtering surgery.

Of note, I do not use toric IOLs if I am combining the cataract procedure with traditional filtering surgery, because the postoperative corneal astigmatism is too difficult to predict. These lenses can be used successfully, however, when cataract surgery is combined with a
more minimally invasive angle-based glaucoma surgery. It is debatable whether these IOLs should be used in the setting of exfoliation disease because of the potential for a decentered lens. Although this may not be an absolute contraindication, thorough informed consent is required.

Monovision and Presbyopia-Correcting IOLs

Other newer IOL technologies and common refractive options may not be advisable in patients with moderate to advanced glaucoma. Although these options are not absolutely contraindicated, I tend to discourage patients with advanced glaucoma from two refractive alternatives in particular.

Monovision

Monovision can be very effective in motivated patients if both of their eyes function normally and they can achieve sensory adaptation. In patients with advanced glaucoma, a permanent visual defect sometimes does not allow one or both eyes to function independently at an adequate level to support monovision. This can be true even if the patient successfully used monovision contact lenses years earlier (Figure). I therefore usually do not recommend monovision for patients with advanced glaucoma. If one of these individuals is extremely motivated to pursue this option, I generally insist on a contact lens trial first.

Presbyopia-Correcting IOLs

Multifocal IOLs can provide spectacle-free postoperative vision to many patients, but the technology is not without its limitations. The ideal candidate for a multifocal IOL is motivated and has a cataract but otherwise normal eyes. Unfortunately, there is little published data to guide the use of multifocal IOLs in this patient population, so surgeons are left mostly with anecdotal experience. Current multifocal IOLs can reduce contrast sensitivity compared with monofocal lenses. (The studies just cited used spherical multifocal IOLs. Newer aspheric multifocal IOLs might perform better in terms of contrast sensitivity.) Because patients with moderate to advanced glaucoma likely already have decreased contrast sensitivity, a further reduction by the IOL is not desirable. Someone with advanced glaucoma, decreased contrast sensitivity, and visual field compromise—often very near fixation—likely will not benefit from the potential advantages of a multifocal IOL. Considering the out-of-pocket expense for this technology, the cost-benefit ratio for these patients is unfavorable.

Another consideration in this population is the effect of multifocal IOLs on visual field testing. Little has been published on the subject, but at least one study reported a reduction in visual sensitivity of up to 2 dB, as mea-

Figure. A 70-year-old woman successfully used monovision contact lenses for many years, her right eye corrected for distance and her left eye for near. The patient desired monovision after cataract surgery (right eye for distance, left eye for near) despite a known visual defect in her left eye (top). After surgery, she successfully used monovision and was free of spectacles for 4 years. The lower visual field shows some glaucomatous progression in both of her eyes during the 4-year period. It is mostly marked by a decrease of 4 dB in the mean deviation for her left eye that is not attributable to any cause other than glaucoma. Although the measured visual acuity is about the same as before, the patient can no longer read well with only her left eye and requires reading spectacles full time. She now considers the surgical anisometropia more of a bother than a benefit.
sured by standard automated perimetry, in patients with a multifocal IOL compared with phakic controls. The researchers found a reduction of 0.8 dB in the multifocal group compared with controls who had a monofocal IOL. After controlling for other variables, the investigators felt that the decrease in sensitivity related to the multifocal IOL design and not to pseudophakia alone. Such a reduction could be significant relative to the interpretation of future standard automated perimetry.

Until more definitive studies are conducted, I will not recommend multifocal IOLs to patients with significant glaucoma. Accommodating IOLs might be more acceptable in these patients in terms of contrast sensitivity, but these lenses certainly have their own limitations in all patient populations.

**CONCLUSION**

Surgeons should carefully discuss IOL selection and refractive options with patients who have glaucoma. For individuals with OHT or early glaucoma, all available modalities merit consideration with little modification. A patient with moderate to severe glaucoma, however, needs to be informed of the potential limitations of some alternatives.

This article is reproduced with permission from Glaucoma Today’s May/June 2014 issue.

Norm Zabriskie, MD, is an associate professor, and he is vice-chairman and director of clinical operations for the John A. Moran Eye Center at the University of Utah School of Medicine in Salt Lake City. Dr. Zabriskie may be reached at (801) 585-3071; norm.zabriskie@hsc.utah.edu.

---